

January 21, 2026

To

BSE Limited,

Listing Department, P J Towers,
Dalal Street,
Mumbai – 400 001.

National Stock Exchange of India Limited,

Listing Department, "Exchange Plaza",
Bandra-Kurla Complex, Bandra (E),
Mumbai - 400 051.

Scrip Code: 540679

Trading Symbol: HALEOSLABS

SUB: STRATEGIC DEVELOPMENT COLLABORATION WITH HRV GLOBAL.

Ref: Reg. 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

We would like to inform that the Company has entered into Strategic Development collaboration with HRV Global Life Sciences Private Limited ("HRV Global") to accelerate development and GMP manufacturing of orphan drug and niche therapeutic Active Pharmaceutical Ingredients (APIs) for regulated and semi-regulated markets.

Key terms of the collaboration:

- ✦ The Company will leverage its USFDA-GMP aligned systems and API manufacturing expertise.
- ✦ HRV Global will contribute its global market access and regulatory execution capabilities.

This collaboration supports the Company's strategic goal to expand into complex and high value APIs catering to underserved therapeutic segments and strengthens the Company' presence in regulated and semi regulated markets including US, EU, Latin America, MENA and APAC, through coordinated development and regulatory pathways.

The Company will make further disclosures as and when there is any material update on the collaboration as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015

Kindly take the same on record and suitably disseminate it to all concerned.

For Haleos Labs Limited

(Formerly known as "SMS Lifesciences India Limited")


Trupti Ranjan Mohanty

Company Secretary



Haleos Labs Limited

(Formerly SMS Lifesciences India Limited)